Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 people in total — 6 in the group receiving duvelisib combined with rituximab, and 7 in the group receiving a placebo combined with rituximab. The trial was designed to compare these two treatments in people with a type of blood cancer, with the main goal of measuring how long participants went without their disease getting worse (called "progression-free survival"). The study was terminated early before it could fully complete. The reported data shows that because the trial was stopped early and so few people were enrolled, the main outcome — progression-free survival — was never formally analysed, and no figures for it were reported. For the secondary outcome, overall response rate (meaning how many participants showed a measurable response to treatment), the reported numbers were: in the duvelisib plus rituximab group, 3 participants had one category of response and 2 had another, while 0 had a third category and 0 had a fourth. In the placebo plus rituximab group, the reported data shows 0 in the first category, 1 in the second, 3 in the third, and 2 in the fourth. The specific labels for each response category were not included in the data provided, so a fuller breakdown cannot be described here. Of the 13 people who started the trial, only 2 completed it — both from the duvelisib group — and none from the placebo group completed it. The reasons for not completing were not detailed in the data provided. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Peripheral Neuropathy Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of slow-growing blood cancer called follicular lymphoma (FL), specifically grade 1, 2, or 3a, confirmed by a biopsy taken within the last 2 years (unless a new biopsy wasn't medically possible)
- Your cancer has been tested and confirmed to have a protein called CD20 on the cancer cells, with that test done within the last 2 years
- Your lymphoma has come back at least once after receiving treatment that included a drug called rituximab, combined with certain types of chemotherapy
- If this is your first relapse, your cancer must have either not responded to chemotherapy or you were unable to tolerate it
- Your cancer came back or got worse within 24 months of starting your last treatment
- You have at least one tumor that is larger than 1.5 cm, visible on a CT, PET, or MRI scan, in an area that has not previously been treated with radiation — or in a previously radiated area that has shown documented growth
Who may not be able to join:
- You have signs of a different type of slow-growing lymphoma (such as marginal zone lymphoma or small lymphocytic lymphoma)
- Your lymphoma has changed into a faster-growing, more aggressive type, or is grade 3b follicular lymphoma
- Your cancer did not respond to rituximab — specifically, if your disease got worse during or within 6 months of completing a rituximab-based treatment
- You have had a severe allergic or serious reaction to rituximab or similar types of antibody-based medicines
- You have previously had a donor stem cell transplant (from another person)
- There is evidence that lymphoma has spread to your brain or spinal cord
- You have previously been treated with a type of drug called a PI3K inhibitor or BTK inhibitor (confirm with trial site if unsure)
- You have had tuberculosis (TB) within the past two years
- You currently have an active serious infection (bacterial, fungal, or viral) that requires intravenous (IV) medication at the time of joining the trial
- You have a current, past, or long-term hepatitis B or hepatitis C infection, or have tested positive for certain hepatitis B or C markers in your blood
- You have had a stroke, a heart attack, unstable chest pain (angina), or a serious irregular heartbeat requiring treatment within the last 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.